Abstracts tagged "Lorecivivint"

Abstract Number: 0729 • ACR Convergence 2021
A Multicenter, Observational, Extension Study Evaluating the Safety, Tolerability, and Efficacy of a Single Lorecivivint Injection in Knee OA Subjects
Ismail Simsek¹, Christopher Swearingen¹, Heli Ghandehari¹, Sarah Kennedy², Jeyanesh Tambiah¹, Yusuf Yazici³ and Nebojsa Skrepnik⁴, ¹Biosplice Therapeutics, Inc., San Diego, CA, ²Biosplice Therapeutics, Inc, San Diego, CA, ³New York University School of Medicine, La Jolla, CA, ⁴Tucson Orthopaedic Institute, Tucson
Background/Purpose: Lorecivivint (LOR), a novel intra-articular (IA) CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways, is in development as a knee osteoarthritis (OA) treatment. To…
Abstract Number: 0730 • ACR Convergence 2021
Safety, Tolerability, and Pharmacokinetics of an Intra-articular Corticosteroid Injection Administered 7 Days Before or After Intra-articular Lorecivivint Injection into the Same Knee of Healthy Volunteers: An Open-Label, Parallel-Arm Study
Amy Halseth¹, Nancy Lane², Sarah Kennedy³, Christopher Swearingen¹, Victor Lopez¹, Ismail Simsek¹, Mark Fineman¹ and Yusuf Yazici⁴, ¹Biosplice Therapeutics, Inc., San Diego, CA, ²University of California Davis, Hillsborough, CA, ³Biosplice Therapeutics, Inc, San Diego, CA, ⁴New York University School of Medicine, La Jolla, CA
Background/Purpose: Knee osteoarthritis (OA) is a painful condition leading to joint damage and impaired function. Intra-articular (IA) corticosteroid injections are frequently prescribed to treat pain.…
Abstract Number: 0941 • ACR Convergence 2021
Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK Inhibitor That Modulates the Wnt Pathway, Provided Cartilage-Protective Effects in an Animal Model of Post-traumatic OA
Timothy Seo¹, Vishal Deshmukh¹ and Yusuf Yazici², ¹Biosplice Therapeutics, Inc., San Diego, CA, ²New York University School of Medicine, La Jolla, CA
Background/Purpose: Osteoarthritis (OA) is characterized by increased cartilage thinning, bone remodeling, and inflammation. Post-traumatic OA, which develops after acute direct trauma to the joints, accounts…
Abstract Number: 1469 • ACR Convergence 2021
Lorecivivint (SM04690), an Intra-articular, Small-Molecule CLK/DYRK Inhibitor That Modulates the Wnt Pathway, as a Potential Treatment for Meniscal Injuries
Timothy Seo¹, Vishal Deshmukh¹ and Yusuf Yazici², ¹Biosplice Therapeutics, Inc., San Diego, CA, ²New York University School of Medicine, La Jolla, CA
Background/Purpose: Meniscal injuries are the most common pathology of the knee and are associated with pain, stiffness, and localized swelling. Meniscal damage is a frequent…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].